Overview

Company name	TMRC Co., Ltd.
Location of head office	MI Bldg., 1-12-12, KitaShinjuku, Shinjuku-ku, Tokyo 169-0074, JAPAN  <Map>
Board Directors	Hirobumi Takeuchi President and CEO Masaki Sudo Board Director Katsuhiro Uto Board Director
Established	January 2002

History

2002	January	Established in Minato-ku, Tokyo, as a Contract Research Organization (CRO) specializing in the field of cancer.

2004	February	Obtained a license for Tamibarotene, and started an R&D business.

2009	March	Spun off CRO business and established it as a subsidiary company, then transferred 100% of stocks to Sugi Medical Co., Ltd.

2014	June	Granted a license for Tamibarotene, for the treatment of Pediatric cancer, to a Japanese company Ohara Pharmaceutical Co., Ltd. in Japanese territory.
	July	Reached an agreement with Children's Hospital Los Angeles (CHLA *) to develop and commercialize TM-411 in neutropenia.

2015	September	Granted a license for Tamibarotene, for the treatment of cancer, to a US company Syros Pharmaceuticals Inc., in North American and European territory.

2017	February	Affiliated under RaQualia Pharma Inc. as wholly owned subsidiary

2021	January	Granted a license for the Biomarker Patent in the Asian territory from Syros Pharmaceuticals Inc.

*Children's Hospital Los Angeles has been named the best children's hospital on the West Coast and among the top five in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. Children's Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. Children's Hospital is also one of America's premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California.

Board Directors

Management Team